Tuning Costimulatory Signaling and Activation Domains in TCR-Like Chimeric Antigen Receptors to Optimize Functional Avidity at Low Antigen-Density Thresholds

Abstract Chimeric antigen receptor (CAR) T-cell therapy has demonstrated remarkable efficacy in hematological malignancies, yet its translation to solid tumors remains limited by heterogeneous and often low target antigen density. TCR-like (TCRL) based CARs, which recognize intracellular antigens presented by major histocompatibility complex (MHC) molecules, significantly expand the targetable landscape for solid tumors such as melanoma. In this study, we systematically investigated how the integration of distinct costimulatory domains (CD28 and 4-1BB) and primary activation elements (CD3ζ versus FcRγ) dictates the functional avidity outcome of TCRL CAR T-cells targeting the melanoma-associated Tyrosinase/HLA-A2 complex. Using a well-defined experimental system with controlled antigen densities, we profiled the phenotypic, cytolytic, and transcriptomic landscapes of multiple second- and third-generation CAR architectures. Our results demonstrate that CD28-based signaling lowers the antigen density threshold required for robust immediate cytotoxicity but renders the T-cells susceptible to rapid exhaustion upon chronic stimulation. In contrast, 4-1BB costimulation confers a distinct transcriptomic fingerprint that limits exhaustion, albeit requiring higher antigen density for optimal initial activation. Crucially, structural tuning of these modules led to the engineering of a novel hybrid CAR construct that integrates both CD3ζ and FcRγ activation domains in a position-dependent manner. This novel hybrid configuration exhibited synergistic signal amplification, overcoming the low-antigen-density barrier and demonstrating superior functional sensitivity in our in vitro models. Together, these exploratory findings elucidate the critical interplay between biophysical binding properties, costimulatory signaling, and primary activation elements, providing a strong rational framework for future in vivo evaluation of optimized TCRL-based CAR T-cell therapies.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-17
DOI
https://doi.org/10.21203/rs.3.rs-11512240/v1
Primary Topic
CAR-T cell therapy research
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Tuning Costimulatory Signaling and Activation Domains in TCR-Like Chimeric Antigen Receptors to Optimize Functional Avidity at Low Antigen-Density Thresholds

Yoram Reiter, Moshe Biton, Ofir Levin-Piaeda, Carmel Sochen et al.
Research Square
CAR-T cell therapy research
preprint

Tuning Costimulatory Signaling and Activation Domains in TCR-Like Chimeric Antigen Receptors to Optimize Functional Avidity at Low Antigen-Density Thresholds

Yoram Reiter, Moshe Biton, Ofir Levin-Piaeda, Carmel Sochen, Maya Cohen, Noam Carmi
preprint en

Abstract

Abstract Chimeric antigen receptor (CAR) T-cell therapy has demonstrated remarkable efficacy in hematological malignancies, yet its translation to solid tumors remains limited by heterogeneous and often low target antigen density. TCR-like (TCRL) based CARs, which recognize intracellular antigens presented by major histocompatibility complex (MHC) molecules, significantly expand the targetable landscape for solid tumors such as melanoma. In this study, we systematically investigated how the integration of distinct costimulatory domains (CD28 and 4-1BB) and primary activation elements (CD3ζ versus FcRγ) dictates the functional avidity outcome of TCRL CAR T-cells targeting the melanoma-associated Tyrosinase/HLA-A2 complex. Using a well-defined experimental system with controlled antigen densities, we profiled the phenotypic, cytolytic, and transcriptomic landscapes of multiple second- and third-generation CAR architectures. Our results demonstrate that CD28-based signaling lowers the antigen density threshold required for robust immediate cytotoxicity but renders the T-cells susceptible to rapid exhaustion upon chronic stimulation. In contrast, 4-1BB costimulation confers a distinct transcriptomic fingerprint that limits exhaustion, albeit requiring higher antigen density for optimal initial activation. Crucially, structural tuning of these modules led to the engineering of a novel hybrid CAR construct that integrates both CD3ζ and FcRγ activation domains in a position-dependent manner. This novel hybrid configuration exhibited synergistic signal amplification, overcoming the low-antigen-density barrier and demonstrating superior functional sensitivity in our in vitro models. Together, these exploratory findings elucidate the critical interplay between biophysical binding properties, costimulatory signaling, and primary activation elements, providing a strong rational framework for future in vivo evaluation of optimized TCRL-based CAR T-cell therapies.

Research Square
Technion – Israel Institute of Technology (IL), Weizmann Institute of Science (IL)
Good health and well-being
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon